“…We excluded 169 because they were reviews, case reports, letters to editor, editorials, case series, retrospective studies, nonparenchymal neurocysticercosis studies, or active comparator trials (comparing 2 agents, e.g., albendazole with praziquantel). Full texts of the remaining 31 were reviewed; 16 were excluded because these contained data previously published, [16][17][18] 4 RCTs studied agents other than anthelminthics or corticosteroids, [19][20][21][22] 5 included patients with multiple enhancing or cystic lesions, 13,[23][24][25][26] and 4 had no control group for comparison. [27][28][29][30] Eventually, 10 RCTs, involving 765 subjects with SCG, were included in the meta-analysis of anthelminthic treatment.…”